ERBB2 and pancreatic adenocarcinoma: HER2 amplification was positively associated with TMB in invasive breast carcinoma, esophageal carcinoma, and pancreatic adenocarcinoma (PAAD), but was negatively associated with TMB in uterine corpus endometrial carcinoma (UCEC) (p<0.05; Supplementary Figure S5).